Download PDF
Semin Neurol 2024; 44(01): 090-101
DOI: 10.1055/s-0043-1777424
Review Article

Neurologic Complications in Adult Cancer Survivorship

Tresa Michelle McGranahan
1   Division of Hematology and Oncology, Scripps Cancer Center, La Jolla, California
,
Karl Cristie Figuracion
2   Department of Radiation Oncology, University of Washington, Seattle, Washington
,
Myron Goldberg
3   Department of Rehabilitation Medicine, University of Washington Medical Center, Seattle, Washington
,
David P. Sheppard
3   Department of Rehabilitation Medicine, University of Washington Medical Center, Seattle, Washington
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Over the past decade, the improvement in cancer diagnostics and therapeutics has extended the overall survival of patients diagnosed with cancer including brain cancer. However, despite these unprecedented medical successes, patients continue to experience numerous neurologic complications after treatment that interfere with their independence, functionality, and overall quality of life. These include, among others, cognitive impairment, endocrinopathies, peripheral and cranial neuropathies, and vasculopathy. This article describes the long-term neurologic complications cancer survivors commonly experience to increase awareness of these complications and discuss treatments when available. Further research is necessary to understanding of mechanisms of neurologic injury and advance diagnosis and treatment. Effective patient education, monitoring, and managing neurologic issues after cancer treatment may improve independence, functionality, and quality of life during survivorship.

Keywords

brain tumor - survivorship - radiation complications - neuropathy


Publication History

Article published online:
06 January 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016; 25 (07) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 2 Országhová Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci 2021; 8: 770413
    CrossrefPubMedGoogle Scholar
  • 3 Lange M, Joly F, Vardy J. et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019; 30 (12) 1925-1940
    CrossrefPubMedGoogle Scholar
  • 4 Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res 2009; 151: 387-419
    CrossrefPubMedGoogle Scholar
  • 5 Whittaker AL, George RP, O'Malley L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis. Sci Rep 2022; 12 (01) 2135
    CrossrefPubMedGoogle Scholar
  • 6 Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases. EMBO Mol Med 2020; 12 (06) e12075
    CrossrefPubMedGoogle Scholar
  • 7 Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry 2014; 26 (01) 102-113
    CrossrefPubMedGoogle Scholar
  • 8 Amidi A, Agerbæk M, Wu LM. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular ca. Brain Imaging Behav 2017; 11: 769-783
    CrossrefPubMedGoogle Scholar
  • 9 Ahles TA, Saykin AJ, Noll WW. et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003; 12 (06) 612-619
    CrossrefPubMedGoogle Scholar
  • 10 Ahles TA, Li Y, McDonald BC. et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology 2014; 23 (12) 1382-1390
    CrossrefPubMedGoogle Scholar
  • 11 Dumont Lecomte D, Lequesne J, Geffrelot J. et al. Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions. Cancer Radiother 2019; 23 (08) 860-866
    CrossrefPubMedGoogle Scholar
  • 12 Small BJ, Rawson KS, Walsh E. et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 2011; 117 (07) 1369-1376
    CrossrefPubMedGoogle Scholar
  • 13 Driver JA, Beiser A, Au R. et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 2012; 344: e1442
    CrossrefPubMedGoogle Scholar
  • 14 Dijkshoorn ABC, van Stralen HE, Sloots M, Schagen SB, Visser-Meily JMA, Schepers VPM. Prevalence of cognitive impairment and change in patients with breast cancer: a systematic review of longitudinal studies. Psychooncology 2021; 30 (05) 635-648
    CrossrefPubMedGoogle Scholar
  • 15 Buchbinder D, Kelly DL, Duarte RF. et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant 2018; 53 (05) 535-555
    CrossrefPubMedGoogle Scholar
  • 16 Feng Y, Zhang XD, Zheng G, Zhang LJ. Chemotherapy-induced brain changes in breast cancer survivors: evaluation with multimodality magnetic resonance imaging. Brain Imaging Behav 2019; 13 (06) 1799-1814
    CrossrefPubMedGoogle Scholar
  • 17 Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12 (07) 703-708
    CrossrefPubMedGoogle Scholar
  • 18 Syed Alwi SM, Narayanan V, Mohd Taib NA, Che Din N. Chemotherapy-related cognitive impairment (CRCI) among early-stage breast cancer survivors in Malaysia. J Clin Exp Neuropsychol 2021; 43 (05) 534-545
    CrossrefPubMedGoogle Scholar
  • 19 Mancusi R, Monje M. The neuroscience of cancer. Nature 2023; 618 (7965) 467-479
    CrossrefPubMedGoogle Scholar
  • 20 Venkatesh HS, Morishita W, Geraghty AC. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 2019; 573 (7775) 539-545
    CrossrefPubMedGoogle Scholar
  • 21 Stoecklein VM, Stoecklein S, Galiè F. et al. Resting-state fMRI detects alterations in whole brain connectivity related to tumor biology in glioma patients. Neuro-oncol 2020; 22 (09) 1388-1398
    CrossrefPubMedGoogle Scholar
  • 22 Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J. et al. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology 2015; 85 (08) 683-691
    CrossrefPubMedGoogle Scholar
  • 23 Johnson DR, Wefel JS. Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol 2013; 2 (02) 195-201
    CrossrefPubMedGoogle Scholar
  • 24 Seibert TM, Karunamuni R, Kaifi S. et al. Cerebral cortex regions selectively vulnerable to radiation dose-dependent atrophy. Int J Radiat Oncol Biol Phys 2017; 97 (05) 910-918
    CrossrefPubMedGoogle Scholar
  • 25 Hoffmann C, Distel L, Knippen S. et al. Brain volume reduction after whole-brain radiotherapy: quantification and prognostic relevance. Neuro-oncol 2018; 20 (02) 268-278
    CrossrefPubMedGoogle Scholar
  • 26 Chapman CH, Zhu T, Nazem-Zadeh M. et al. Diffusion tensor imaging predicts cognitive function change following partial brain radiotherapy for low-grade and benign tumors. Radiother Oncol 2016; 120 (02) 234-240
    CrossrefPubMedGoogle Scholar
  • 27 Brown PD, Gondi V, Pugh S. et al; For NRG Oncology. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 2020; 38 (10) 1019-1029
    CrossrefPubMedGoogle Scholar
  • 28 Lange M, Joly F. How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Pract 2017; 13 (12) 784-790
    CrossrefPubMedGoogle Scholar
  • 29 Campbell KL, Zadravec K, Bland KA, Chesley E, Wolf F, Janelsins MC. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys Ther 2020; 100 (03) 523-542
    CrossrefPubMedGoogle Scholar
  • 30 Dos Santos M, Hardy-Léger I, Rigal O. et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: a 3-arm randomized trial. Cancer 2020; 126 (24) 5328-5336
    CrossrefPubMedGoogle Scholar
  • 31 Erickson D, Donegan D. Diagnosis and management of neuroendocrine disorders of survivors of brain tumors. Am Soc Clin Oncol Educ Book 2021; 41: 1-9
    CrossrefPubMedGoogle Scholar
  • 32 Chemaitilly W, Li Z, Huang S. et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol 2015; 33 (05) 492-500
    CrossrefPubMedGoogle Scholar
  • 33 van Iersel L, Li Z, Srivastava DK. et al. Hypothalamic-pituitary disorders in childhood cancer survivors: prevalence, risk factors and long-term health outcomes. J Clin Endocrinol Metab 2019; 104 (12) 6101-6115
    CrossrefPubMedGoogle Scholar
  • 34 Barroso-Sousa R, Barry WT, Garrido-Castro AC. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4 (02) 173-182
    CrossrefPubMedGoogle Scholar
  • 35 Inskip PD, Veiga LHS, Brenner AV. et al. Hypothyroidism after radiation therapy for childhood cancer: a report from the childhood cancer survivor study. Radiat Res 2018; 190 (02) 117-132
    CrossrefPubMedGoogle Scholar
  • 36 Barroso-Sousa R, Barry WT, Garrido-Castro AC. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018; 4 (02) 173-182
    CrossrefPubMedGoogle Scholar
  • 37 Eaton BR, Esiashvili N, Kim S. et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro-oncol 2016; 18 (06) 881-887
    CrossrefPubMedGoogle Scholar
  • 38 Lawrie TA, Gillespie D, Dowswell T. et al. Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database Syst Rev 2019; 8 (08) CD013047
    PubMedGoogle Scholar
  • 39 Gabel N, Altshuler DB, Brezzell A. et al. Health related quality of life in adult low and high-grade glioma patients using the National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) and Neuro-QOL Assessments. Front Neurol 2019; 10: 212
    CrossrefPubMedGoogle Scholar
  • 40 Omran M, Belcher EK, Mohile NA. et al. Review of the role of the brain in chemotherapy-induced peripheral neuropathy. Front Mol Biosci 2021; 8: 693133
    CrossrefPubMedGoogle Scholar
  • 41 Kamgar M, Greenwald MK, Assad H. et al. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Med 2021; 10 (19) 6666-6676
    CrossrefPubMedGoogle Scholar
  • 42 Molassiotis A, Cheng HL, Leung KT. et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019; 9 (06) e01312
    CrossrefPubMedGoogle Scholar
  • 43 Smith EM, Pang H, Cirrincione C. et al; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309 (13) 1359-1367
    CrossrefPubMedGoogle Scholar
  • 44 Delanian S, Lefaix JL, Pradat PF. Radiation-induced neuropathy in cancer survivors. Radiother Oncol 2012; 105 (03) 273-282
    CrossrefPubMedGoogle Scholar
  • 45 Rudra S, Roy A, Brenneman R. et al. Radiation-induced brachial plexopathy in patients with breast cancer treated with comprehensive adjuvant radiation therapy. Adv Radiat Oncol 2020; 6 (01) 100602
    CrossrefPubMedGoogle Scholar
  • 46 Miran C, Bonnet E, Lafont C. et al. Radiation induced brachial plexopathy: diagnosis, risk factors, principles of care. Cancer Radiother 2022; 27 (02) 163-169
    PubMedGoogle Scholar
  • 47 de Oliveira AJM, Castro JPS, Foroni LH, Siqueira MG, Martins RS. Treatment of radiation-induced brachial plexopathy with omentoplasty. Autops Case Rep 2020; 10 (03) e2020202
    CrossrefPubMedGoogle Scholar
  • 48 Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol 2019; 17 (02) 184-196
    CrossrefPubMedGoogle Scholar
  • 49 Pritchard J, Anand P, Broome J. et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol 2001; 58 (03) 279-286
    CrossrefPubMedGoogle Scholar
  • 50 Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold Jr SC. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994; 44 (11) 2020-2027
    CrossrefPubMedGoogle Scholar
  • 51 Indaram M, Ali FS, Levin MH. In search of a treatment for radiation-induced optic neuropathy. Curr Treat Options Neurol 2015; 17 (01) 325
    CrossrefPubMedGoogle Scholar
  • 52 Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30 (04) 765-773
    CrossrefPubMedGoogle Scholar
  • 53 Ataídes FG, Silva SFBR, Baldin JJCMC. Radiation-induced optic neuropathy: literature review. Neuroophthalmology 2020; 45 (03) 172-180
    CrossrefPubMedGoogle Scholar
  • 54 Parrozzani R, Frizziero L, Londei D. et al. Peripapillary vascular changes in radiation optic neuropathy: an optical coherence tomography angiography grading. Br J Ophthalmol 2018; 102 (09) 1238-1243
    CrossrefPubMedGoogle Scholar
  • 55 AlAmeer AM, Davis JB, Carey AR, Henderson AD. Outcomes of systemic bevacizumab in radiation-induced optic neuropathy, case series. J Neurooncol 2023; 163 (02) 439-446
    CrossrefPubMedGoogle Scholar
  • 56 Farooq O, Lincoff NS, Saikali N, Prasad D, Miletich RS, Mechtler LL. Novel treatment for radiation optic neuropathy with intravenous bevacizumab. J Neuroophthalmol 2012; 32 (04) 321-324
    CrossrefPubMedGoogle Scholar
  • 57 Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol 1966; 50 (03) 147-155
    CrossrefPubMedGoogle Scholar
  • 58 Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 2008; 28 (07) 964-968
    CrossrefPubMedGoogle Scholar
  • 59 Zuur CL, Simis YJ, Lansdaal PE. et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 2007; 68 (05) 1320-1325
    CrossrefPubMedGoogle Scholar
  • 60 Talach T, Rottenberg J, Gal B. et al. Genetic risk factors of cisplatin induced ototoxicity in adult patients. Neoplasma 2016; 63 (02) 263-268
    PubMedGoogle Scholar
  • 61 Schuette A, Lander DP, Kallogjeri D. et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 2020; 146 (02) 106-112
    CrossrefPubMedGoogle Scholar
  • 62 Massimino M, Sunyach MP, Barretta F. et al. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients. J Neurooncol 2020; 148 (03) 619-628
    CrossrefPubMedGoogle Scholar
  • 63 Miaskowski C, Paul SM, Mastick J. et al. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy. Eur J Oncol Nurs 2018; 32: 1-11
    CrossrefPubMedGoogle Scholar
  • 64 Cuoco S, Cappiello A, Scarpa A. et al. Neuropsychological profile of hearing-impaired patients and the effect of hearing aid on cognitive functions: an exploratory study. Sci Rep 2021; 11 (01) 9384
    CrossrefPubMedGoogle Scholar
  • 65 Figuracion KCF, Halasz LM, Lam NY. et al. Surveillance of long-term complications after treatment of adult brain tumor survivors-review and evidence-based recommendations. Neurooncol Pract 2022; 9 (06) 475-486
    PubMedGoogle Scholar
  • 66 Rovetti J, Goy H, Pichora-Fuller MK, Russo FA. Functional near-infrared spectroscopy as a measure of listening effort in older adults who use hearing aids. Trends Hear 2019; 23: 2331216519886722
    CrossrefPubMedGoogle Scholar
  • 67 Sarant J, Harris D, Busby P. et al. The effect of hearing aid use on cognition in older adults: can we delay decline or even improve cognitive function?. J Clin Med 2020; 9 (01) 254
    CrossrefPubMedGoogle Scholar
  • 68 Zaorsky NG, Zhang Y, Tchelebi LT, Mackley HB, Chinchilli VM, Zacharia BE. Stroke among cancer patients. Nat Commun 2019; 10 (01) 5172
    CrossrefPubMedGoogle Scholar
  • 69 Nguyen T, DeAngelis LM. Stroke in cancer patients. Curr Neurol Neurosci Rep 2006; 6 (03) 187-192
    CrossrefPubMedGoogle Scholar
  • 70 Campen CJ, Kranick SM, Kasner SE. et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke 2012; 43 (11) 3035-3040
    CrossrefPubMedGoogle Scholar
  • 71 Ullrich NJ, Robertson R, Kinnamon DD. et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 2007; 68 (12) 932-938
    CrossrefPubMedGoogle Scholar
  • 72 Desai SS, Paulino AC, Mai WY, Teh BS. Radiation-induced moyamoya syndrome. Int J Radiat Oncol Biol Phys 2006; 65 (04) 1222-1227
    CrossrefPubMedGoogle Scholar
  • 73 Komlodi-Pasztor E, Gilbert MR, Armstrong TS. Diagnosis and management of stroke in adults with primary brain tumor. Curr Oncol Rep 2022; 24 (10) 1251-1259
    CrossrefPubMedGoogle Scholar
  • 74 Figuracion KCF, Jung W, Martha SR. Ischemic stroke risk among adult brain tumor survivors: evidence to guide practice. J Neurosci Nurs 2021; 53 (05) 202-207
    CrossrefPubMedGoogle Scholar
  • 75 Kleinschmidt-DeMasters BK, Lillehei KO. Radiation-induced cerebral vascular “malformations” at biopsy. J Neuropathol Exp Neurol 2016; 75 (11) 1081-1092
    CrossrefPubMedGoogle Scholar
  • 76 Patet G, Bartoli A, Meling TR. Natural history and treatment options of radiation-induced brain cavernomas: a systematic review. Neurosurg Rev 2022; 45 (01) 243-251
    CrossrefPubMedGoogle Scholar
  • 77 Lew SM, Morgan JN, Psaty E, Lefton DR, Allen JC, Abbott R. Cumulative incidence of radiation-induced cavernomas in long-term survivors of medulloblastoma. J Neurosurg 2006; 104 (02) 103-107
    PubMedGoogle Scholar
  • 78 Hong CE, Cho YD, Yoo DH, Bae JW, Oh HS, Kang HS. Gamma knife radiosurgery-induced intracranial aneurysms: a case series and literature review. J Neuroradiol 2023; 50 (01) 36-39
    CrossrefPubMedGoogle Scholar
  • 79 Yang WH, Yang YH, Chen PC. et al. Intracranial aneurysms formation after radiotherapy for head and neck cancer: a 10-year nationwide follow-up study. BMC Cancer 2019; 19 (01) 537
    CrossrefPubMedGoogle Scholar
  • 80 Uchikawa H, Nishi T, Kaku Y, Goto T, Kuratsu JI, Yano S. Delayed development of aneurysms following gamma knife surgery for trigeminal neuralgia: report of 2 cases. World Neurosurg 2017; 99: 813.e13-813.e19
    CrossrefPubMedGoogle Scholar
  • 81 Dominguez L, Saway B, Benko MJ, Guilliams E, Marvin EA, Entwistle JJ. Ruptured distal superior cerebellar artery aneurysm after gamma knife radiosurgery for trigeminal neuralgia: a case report and review of the literature. World Neurosurg 2020; 135: 2-6
    CrossrefPubMedGoogle Scholar
  • 82 Paolucci A, Schisano L, Pluderi M. et al. Giant intracranial aneurysm following radiation therapy: literature review with a novel case discussion. Acta Biomed 2020; 91 (10-S): e2020005
    PubMedGoogle Scholar
  • 83 Nanney III AD, El Tecle NE, El Ahmadieh TY. et al. Intracranial aneurysms in previously irradiated fields: literature review and case report. World Neurosurg 2014; 81 (3-4): 511-519
    CrossrefPubMedGoogle Scholar
  • 84 Dominguez M, Malani R. Stroke-like migraine attacks after radiation therapy (SMART) syndrome: a comprehensive review. Curr Pain Headache Rep 2021; 25 (05) 33
    CrossrefPubMedGoogle Scholar
  • 85 Armstrong AE, Gillan E, DiMario Jr FJ. SMART syndrome (stroke-like migraine attacks after radiation therapy) in adult and pediatric patients. J Child Neurol 2014; 29 (03) 336-341
    CrossrefPubMedGoogle Scholar
  • 86 Glimelius B, Manojlovic N, Pfeiffer P. et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol 2018; 57 (03) 393-402
    CrossrefPubMedGoogle Scholar
  • 87 Jia J, Guo Y, Sundar R, Bandla A, Hao Z. Cryotherapy for prevention of taxane-induced peripheral neuropathy: a meta-analysis. Front Oncol 2021; 11: 781812
    CrossrefPubMedGoogle Scholar
  • 88 Kleckner IR, Kamen C, Gewandter JS. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26 (04) 1019-1028
    CrossrefPubMedGoogle Scholar
  • 89 Aghili M, Zare M, Mousavi N. et al. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: a randomized placebo controlled clinical trial. Breast J 2019; 25 (02) 226-231
    CrossrefPubMedGoogle Scholar
  • 90 Yehia R, Saleh S, El Abhar H, Saad AS, Schaalan M. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a perspective on targeting Nrf-2 and NF-κB pathways. Toxicol Appl Pharmacol 2019; 365: 41-50
    CrossrefPubMedGoogle Scholar
  • 91 Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer 2017; 25 (01) 195-204
    CrossrefPubMedGoogle Scholar
  • 92 Miao H, Li R, Chen D. et al. Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: a meta-analysis of randomized controlled trials. Ann Nutr Metab 2021; 77 (03) 127-137
    CrossrefPubMedGoogle Scholar
  • 93 Bonm A, Taylor LP. Management of neurologic complications in patients with brain and spine tumors. Semin Neurol 2024; 44 (01) 53-63
    Article in Thieme ConnectPubMedGoogle Scholar